4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

12.86 -0.06 (-0.46%)

Delayed Quote Updated: 12:15 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about 4D Molecular Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Analyst Expectations For 4D Molecular Therapeutics's Future ↗

November 14, 2024

Via Benzinga

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

November 14, 2024

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

November 13, 2024

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference

September 23, 2024

Preclinical data for 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators to be presented in a poster presentation

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

The Latest Analyst Ratings For 4D Molecular Therapeutics ↗

September 09, 2024

Via Benzinga

Peeling Back The Layers: Exploring 4D Molecular Therapeutics Through Analyst Insights ↗

July 18, 2024

Via Benzinga

4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate ↗

September 19, 2024

4D Molecular Therapeutics stock drops after the company shared interim data from the PRISM Phase 1/2 trial and details on its Phase 3 4FRONT study for wet AMD. The Phase 3 study comparing 4D-150 to...

Via Benzinga

4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day

September 18, 2024

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm

September 17, 2024

From Kaskela Law LLC

Via Business Wire

FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

September 12, 2024

From The Schall Law Firm

Via Business Wire

Assessing 4D Molecular Therapeutics: Insights From 7 Financial Analysts ↗

June 26, 2024

Via Benzinga

Analyst Expectations For 4D Molecular Therapeutics's Future ↗

June 07, 2024

Via Benzinga

4DMT Announces Presentations at Upcoming Retina Conferences

September 05, 2024

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT to Participate in the 2024 Cantor Global Healthcare Conference

September 03, 2024

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024

August 27, 2024

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

August 12, 2024

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS for Q2 2024 ↗

August 09, 2024

FDMT stock results show that 4D Molecular Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights

August 08, 2024

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board

August 05, 2024

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

July 29, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

July 21, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

July 18, 2024

Via Benzinga

FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

July 17, 2024

From The Schall Law Firm

Via Business Wire

4D Molecular Therapeutics Goes Neck To Neck With Rival, Shares New Phase 2 Data For Its Wet AMD Candidate ↗

July 17, 2024

4D Molecular Therapeutics reports 24-week interim data from its PRISM Phase 2 trial, showing 77% of wet AMD patients injection-free with 4D-150. The trial highlights safety and efficacy in reducing...

Via Benzinga

4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity

July 17, 2024

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

July 17, 2024

Via Benzinga

4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy

June 24, 2024

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast

June 18, 2024

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

June 08, 2024

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside ↗

June 07, 2024

Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.